NMP 22 - a marker for early detection of bladder cancer and tumour after-care

Bladder cancer is often identified too late. 25-30 % of patients already have invasive cancer at the time of diagnosis. Approximately 70 % of patients suffers a relapse.
Risk factors for bladder cancer are smoking, long-term pain reliever abuse, chronic inflammation of the urogenital tract and working in the chemical industry. The test detects the presence of a tumour-associated nuclear matrix protein (NMP) in the urine. Sensitivity of the test: 82-94 %, depending on the tumour stage. By combining both methods (NMP 22 plus urine cytology), nearly 100 % sensitivity can be achieved.
For the specificity, NMP 22 achieves a value of 90 %. The test makes possible the early prediction of bladder cancer and accurate monitoring of patients after a tumorectomy.

Exclusion criteria
Acute urinary tract infection, catheter, existing stones, chemotherapy, infiltrating foreign tumours (prostate, intestine, kidney), within a period of two weeks before a urine sample, an invasive intervention (catheter, operation) – otherwise, there may be false positive test results.

Test material
10 ml of urine (spontaneous urine). The urine sample should be taken in the morning.

Sampling instruction
Urine must be put immediately in a special container with blue stabiliser liquid. Please request special containers for NMP 22 from the laboratory!

Reference range
< 10 U/ml


Screening and monitoring for bladder cancer; Refining the use of NMP 22 Lee E. Ponsky et al., The Journal of Urology, Vol. 166, 75-78, July 2001

To top